SAAK

Home/Tag: SAAK

Adjuvant Imatinib Study Updates Results

A recent study further documented the advantage of three years of adjuvant imatinib versus one year in high-risk GIST patients. The study, which is to be published in the Journal of Clinical Oncology, was authored by [...]

By |2018-10-30T13:56:09-04:00December 16th, 2015|Gleevec, News, Newsletter, Research, Survival Strategies|

LRG Research Team Member Anette Duensing Receives 2014 GIST Award

The GIST Group Switzerland recently awarded its Science Prize to Dr. Anette Duensing, Assistant Professor of Pathology at the University of Pittsburgh Cancer Institute, and a member of the LRG’s Research Team. GIST Group [...]

By |2018-09-10T10:19:51-04:00February 4th, 2015|News, Research|
Go to Top